Stephanie joined OUP in 2015 and focuses on investments in therapeutics, diagnostics, and medical devices across all stages of development. She led OUP’s investments in Landos Biopharma, Fortis Therapeutics, Pionyr Immunotherapeutics (acquired by Gilead), Modis Therapeutics (acquired by Zogenix), Cell Design Labs (acquired by Gilead), and others. Previously, Stephanie was with H.I.G. BioVentures, a venture capital firm that makes investments in the life sciences sector.
Earlier in her career, Stephanie was a Senior Consultant with Scisive Consulting (now Bionest Partners), a boutique strategy consulting firm focused exclusively on the healthcare industry. At Scisive, she worked with a wide range of clients to provide strategic, financial, and business development support.
Stephanie earned her Ph.D. in Cell Biology from Columbia University where she studied the role of molecular motor proteins in cell division and holds a B.S. in Biology from Muhlenberg College.